Breakout above 2.2? and possible gap fill toward upside.
The FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 9:4, with the majority favoring treatment with the drug as monotherapy.
FDA decision soon. Risk is traditional sell the news event.
The FDA’s Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 9:4, with the majority favoring treatment with the drug as monotherapy.
FDA decision soon. Risk is traditional sell the news event.